drugset

drugset / Trial / NCT01122875

A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

NCT01122875 ↗

Phase 1 Completed 14 enrolled Genentech, Inc.

RandomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.

Timeline

Start: 2010-11
Primary completion: 2012-05
Completion: 2012-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vofatamab	Monoclonal antibody	—	Intravenous

Indications